Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

NCT03534804 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03534804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03534804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2018
Completion date
April 15, 2024
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, metastatic urothelial carcinoma